Sep 22, 2022
CLS-Therapeutics’ project has been selected as one of the semi-finalists to the Hangzhou Innovation & Entrepreneurship Competition

NEW YORK, NY /  September 22, 2022 / CLS Therapeutics,  cancer gene therapy company utilizing a novel therapeutic target, announces that its project  been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.

A presentation named “Anticancer Gene Therapy Platform Addressing A Novel Target to Treat Patients” will showcase CLS’ data for the use of CLS-014 drug candidate as a platform technology to treat various cancers. CLS has identified a new therapeutic target for the successful anticancer therapy for multiple cancers: tumor- and neutrophils- derived cell-free DNA.  Today, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies. The Company uses smart chimeric AAV technology for the delivery of the DNase I transgene to the liver, after which, hepatocytes start to produce a recombinant human DNase enzyme that destroys this cell-free DNA within tumor tissue.

The data that will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics. 

May 10, 2019

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.

Apr 01, 2019

NEW YORK, April 1, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Frontiers in Cancer Immunotherapy” being held on May 14-15, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed) encoding DNase I of the treatment of pancreatic cancer animal model.

Apr 08, 2020

NEW YORK, NY /  April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.